BD today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its EnCor EnCompass™ Breast Biopsy and Tissue Removal System, positioning the company to introduce a state-of-the-art, multi-modality platform to the market in early 2026. The system supports procedures across stereotactic, ultrasound and tomosynthesis-guided imaging, and offers adjustable vacuum strength (high and low), a variable sample notch for on-the-fly customization, and 360° sampling capability for lesions throughout the breast. An echogenic cutting cannula and illuminated sample container enhance visualization, while a choice of 12G, 10G and 7G probes accommodates a broad range of lesion types. BD executives note that this clearance expands the company’s breast health portfolio, underlining its commitment to early detection and procedural efficiency in interventional oncology.

Effective January 20, BD has appointed Shawn Bevec as Senior Vice President of Investor Relations, reporting directly to Interim CFO Vitor Roque until a permanent finance head is in place. Bevec joins from Quest Diagnostics, where he served as Vice President of Investor Relations and led all earnings communications and capital markets engagement. His prior experience includes equity research coverage of health care services and medical devices at Deutsche Bank and Susquehanna International Group, and R&D roles at Pfizer and Johnson & Johnson. Bevec holds a B.S. in Chemistry from the University of Arizona and an MBA in General Management from NYU’s Stern School of Business. Company leadership expects his deep sector knowledge to sharpen BD’s messaging around its growth strategy and value-creation initiatives.